TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34142567

Group type: EXPERIMENTAL
Intervention: Isotonic seawater spray containing chamomile liquid extract (Group A)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Isotonic seawater spray (Group B)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Isotonic seawater nasal irrigation (Group C)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Nasal steroid spray without nasal washing treatment (Group D)
Number of subjects: 123
Study: 34102371

Group type: EXPERIMENTAL
Intervention: Nursing intervention program (education support and patient monitoring)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Nursing intervention program
Number of subjects: 143
Study: 35819445

Group type: EXPERIMENTAL
Intervention: Liberal transfusion thresholds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Restrictive transfusion thresholds
Number of subjects: 0
Study: 34307701

Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VDL)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 158
Study: 34982322

Group type: EXPERIMENTAL
Intervention: Hilotherapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Frozen gloves
Number of subjects: 62
Study: 34672949

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a plus remdesivir
Number of subjects: 969

Group type: COMPARATOR
Intervention: Placebo plus remdesivir
Number of subjects: 969
Study: 32618258

Group type: EXPERIMENTAL
Intervention: Preventive zinc (PZ) tablets (7 mg/day)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP; containing 10 mg zinc and 14 other micronutrients)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Therapeutic zinc (TZ) supplements for diarrhea treatment (20 mg/day for 10 days)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 720
Study: 35449200

Group type: EXPERIMENTAL
Intervention: Single-vision contact lenses (Lens 1)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Progressive contact lenses (Lens 2)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bifocal contact lenses (Lens 3)
Number of subjects: 19
Study: 34290965

Group type: EXPERIMENTAL
Intervention: Saffron (100 mg/day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 32963047

Group type: EXPERIMENTAL
Intervention: Romilkimab 200 mg subcutaneously once a week for 24 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 35242094

Group type: EXPERIMENTAL
Intervention: Liuzijue Qigong (LQG) exercise combined with conventional rehabilitation training
Number of subjects: 160

Group type: COMPARATOR
Intervention: Core Stability Training (CST) combined with conventional rehabilitation training
Number of subjects: 160
Study: 34550903

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 302
Study: 34530470

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 34529114

Group type: COMPARATOR
Intervention: Caffeine 0 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Caffeine 2 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Caffeine 4 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Caffeine with CYP1A2 (rs762551) genotype
Number of subjects: 100
Study: 34625016

Group type: EXPERIMENTAL
Intervention: Working Together intervention (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist control group (n=20)
Number of subjects: 40
Study: 32569031

Group type: EXPERIMENTAL
Intervention: Lubiprostone
Number of subjects: 3209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3209
Study: 33160407

Group type: EXPERIMENTAL
Intervention: Pheromone + insecticide (PI)
Number of subjects: 3145

Group type: EXPERIMENTAL
Intervention: Dog collars (DC)
Number of subjects: 3145

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 3145
Study: 35927505

Group type: EXPERIMENTAL
Intervention: CPAP and lifestyle intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: CPAP only (control)
Number of subjects: 60
Study: 32672145

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 131
Study: 32691672

Group type: EXPERIMENTAL
Intervention: BIOF2 (bioactive cell-free formulation)
Number of subjects: 3
Study: 32468686

Group type: EXPERIMENTAL
Intervention: Video psychoeducation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brochure psychoeducation
Number of subjects: 0
Study: 33474962

Group type: COMPARATOR
Intervention: Full endoscopic discectomy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Full endoscopic discectomy and annular repair
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Full endoscopic discectomy annular repair and ACP intradiscal injection
Number of subjects: 75
Study: 36456831

Group type: EXPERIMENTAL
Intervention: Strategy 1 and Strategy 2 (combined)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Strategy 2
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 247
Study: 34384742

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography (CTA)
Number of subjects: 10001

Group type: EXPERIMENTAL
Intervention: Non-coronary vascular disease (NCVD)
Number of subjects: 10001

Group type: EXPERIMENTAL
Intervention: NCVD
Number of subjects: 10001
Study: 36368290

Group type: EXPERIMENTAL
Intervention: ELLIPTA inhaler
Number of subjects: 114

Group type: COMPARATOR
Intervention: BREEZHALER inhaler
Number of subjects: 114
Study: 33965187

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall survival, progression-free survival, relapse rate, and nonrelapse mortality
Number of subjects: 60
Study: 32135337

Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR) - reduced by 1.5 hours a night for 6 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Habitual sleep (HS)
Number of subjects: 41
Study: 35147905

Group type: EXPERIMENTAL
Intervention: 5-session skin cancer prevention curriculum based on Protection Motivation Theory (PMT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 104
Study: 32061834

Group type: EXPERIMENTAL
Intervention: Couple-Based Meditation (CBM) program; 4 weekly sessions of 60 minutes each via FaceTime.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 22
Study: 35063205

Group type: EXPERIMENTAL
Intervention: LCω3 (MAG‐EPA 3 g daily)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Open retropubic radical prostatectomy
Number of subjects: 130
Study: 33094551

Group type: EXPERIMENTAL
Intervention: Group 2 - SmearOFF™
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Group 3 - Qmix®
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Group 1 - 17% EDTA, Saline and 2% Chlorhexidine solution
Number of subjects: 52

Group type: COMPARATOR
Intervention: Group 4 - saline control
Number of subjects: 52
Study: 32564499

Group type: EXPERIMENTAL
Intervention: Binaural Beats (BB) at 5Hz for 30 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binaural Beats (BB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham Stimulation (SS)
Number of subjects: 0
Study: 35459252

Group type: EXPERIMENTAL
Intervention: Proactive telephone-based peer support for breastfeeding
Number of subjects: 10
Study: 36316913

Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (NSS)
Number of subjects: 50
Study: 34499174

Group type: EXPERIMENTAL
Intervention: Multicomponent treatment (pain neuroscience education, therapeutic exercise, cognitive behavioral therapy, and mindfulness, delivered in 2-hour weekly sessions for 12 weeks)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Multicomponent treatment
Number of subjects: 272

Group type: COMPARATOR
Intervention: Treatment as usual (mainly pharmacological treatment)
Number of subjects: 272
Study: 35288073

Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve (model FP7)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Baerveldt glaucoma implant (model 101‐350)
Number of subjects: 621
Study: 32448384

Group type: EXPERIMENTAL
Intervention: Experimental hip strengthening exercise (group C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: ITB stretching (group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional exercise (group B)
Number of subjects: 24
Study: 33390465

Group type: EXPERIMENTAL
Intervention: Sub-Cohort Study methodology including face-to-face assessment of neuropsychiatric development, body measurement, paediatrician's examination, blood/urine collection for clinical testing and chemical analysis, and home visits.
Number of subjects: 10302

Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 1.5 and 3 years old for home visits, and 2, 4, 6, and 8 years old for developmental/medical examination.
Number of subjects: 10302
Study: 32391579

Group type: EXPERIMENTAL
Intervention: DFMO maintenance therapy for HRNB after standard COG induction, consolidation and immunotherapy for 2 years
Number of subjects: 81

Group type: COMPARATOR
Intervention: Historical control group (76 HRNB patients treated at Beat Childhood Cancer Research Consortium hospitals, disease-free after standard therapy, no DFMO)
Number of subjects: 81
Study: 32722957

Group type: EXPERIMENTAL
Intervention: Isotretinoin 0.5 mg/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35550639

Group type: EXPERIMENTAL
Intervention: Remote e-Consent implementation
Number of subjects: 63

Group type: COMPARATOR
Intervention: Old methods of recruitment (in-person consent)
Number of subjects: 63
Study: 32811628

Group type: EXPERIMENTAL
Intervention: EMI only
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: EMA only
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Both EMI and EMA
Number of subjects: 401

Group type: COMPARATOR
Intervention: Control condition (neither EMI nor EMA)
Number of subjects: 401
Study: 36480039

Group type: EXPERIMENTAL
Intervention: Preoperative telehealth call
Number of subjects: 0

Group type: COMPARATOR
Intervention: No telehealth call (control)
Number of subjects: 0
Study: 34114840

Group type: EXPERIMENTAL
Intervention: Randomized benchmarking algorithm using Weyl unitaries
Number of subjects: 0
Study: 35093318

Group type: EXPERIMENTAL
Intervention: Corticosteroids and nebulized epinephrine
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 210
Study: 34283997

Group type: EXPERIMENTAL
Intervention: 12-month, individually tailored, progressive, physiotherapist-supervised physical exercise twice a week (n=150)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (n=149)
Number of subjects: 300
Study: 32221070

Group type: EXPERIMENTAL
Intervention: HT CBP
Number of subjects: 95
Study: 33358164

Group type: EXPERIMENTAL
Intervention: Zn amino acid complex (ZA; 40 mg/kg DM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heat stress (HS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heat stress (HS) and pair-fed (PF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heat stress and nutrient restriction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pair-fed (PF)
Number of subjects: 40
Study: 32398578

Group type: EXPERIMENTAL
Intervention: Semirecumbent position
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 36

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group A (SR then RL)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group B (RL then SR)
Number of subjects: 36
Study: 35139082

Group type: EXPERIMENTAL
Intervention: Individual-benefits reminder
Number of subjects: 48125

Group type: EXPERIMENTAL
Intervention: Individual- and social-benefits reminder
Number of subjects: 48125

Group type: COMPARATOR
Intervention: No reminder (control treatment)
Number of subjects: 48125

Group type: EXPERIMENTAL
Intervention: Any type of reminder letter
Number of subjects: 48125

Group type: EXPERIMENTAL
Intervention: Individual-benefit reminder vs Individual- and social-benefit reminder
Number of subjects: 48125
Study: 33259700

Group type: EXPERIMENTAL
Intervention: Randomized configuration targeted integration (RCTI) CLD approach for expression of complex molecules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard targeted integration (TI) CLD
Number of subjects: 0
Study: 34851734

Group type: EXPERIMENTAL
Intervention: Fentanyl (75 µg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 28
Study: 32197936

Group type: EXPERIMENTAL
Intervention: PSA-based screening (two rounds at 4-6 year intervals, biopsy recommended if PSA>=3.0 ng/mL)
Number of subjects: 80696

Group type: COMPARATOR
Intervention: Control group (no PSA testing information provided, physicians and patients' decision)
Number of subjects: 80696
Study: 35201549

Group type: EXPERIMENTAL
Intervention: Personalized goal-directed hemodynamic management
Number of subjects: 180

Group type: COMPARATOR
Intervention: Routine hemodynamic management
Number of subjects: 180
Study: 35685659

Group type: EXPERIMENTAL
Intervention: Narrowband Imaging (NBI) mode
Number of subjects: 64

Group type: COMPARATOR
Intervention: Normal white light mode
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: EUS combined with NBI diagnosis
Number of subjects: 64
Study: 32282882

Group type: EXPERIMENTAL
Intervention: IVMP 30 mg/kg followed by IVIG (Gamunex 10%) 1 g/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: IVIG (placebo)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: IVMP + IVIG
Number of subjects: 32
Study: 35355827

Group type: EXPERIMENTAL
Intervention: Neutral Sodium Fluoride (NaF) oral rinse (Colgate® PreviDent® Dental Rinse‐0.2% NaF) weekly for 6 months
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acidulated Phosphate Fluoride (APF) oral rinse (Colgate® Ortho Defense@ PhosFlur® Rinse‐0.044% w/v of NaF) daily for 6 months
Number of subjects: 90
Study: 34147154

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine mass drug administration (MDA) with a target total dose of 7 mg/kg dihydroartemisinin and 55 mg/kg piperaquine, delivered in three rounds over a period from March 4 to May 10, 2015.
Number of subjects: 2671

Group type: COMPARATOR
Intervention: Control group receiving routine malaria case management and long-lasting insecticidal bed-nets (LLINs) without MDA.
Number of subjects: 2671

Group type: EXPERIMENTAL
Intervention: Adverse events monitoring for individuals treated with MDA.
Number of subjects: 2671
Study: 34028126

Group type: EXPERIMENTAL
Intervention: Neratinib plus Capecitabine (N + C) - Neratinib 240 mg per day, Capecitabine 750 mg/m2 twice daily
Number of subjects: 101

Group type: COMPARATOR
Intervention: Lapatinib plus Capecitabine (L + C) - Lapatinib 1,250 mg per day, Capecitabine 1,000 mg/m2 twice daily
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Neratinib plus Capecitabine (N + C)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Lapatinib plus Capecitabine (L + C)
Number of subjects: 101
Study: 34790253

Group type: EXPERIMENTAL
Intervention: Elgucare (Chinese herbal formula)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 32709500

Group type: EXPERIMENTAL
Intervention: Hospital-based pulmonary rehabilitation (Group 1)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Home-based pulmonary rehabilitation (Group 2)
Number of subjects: 67
Study: 36054295

Group type: EXPERIMENTAL
Intervention: Home-based primary care (HBPC)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Office-based primary care (Control)
Number of subjects: 229
Study: 36858753

Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 123
Study: 32998825

Group type: EXPERIMENTAL
Intervention: Preoperative balloon aortic valvuloplasty (BAV)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (no BAV)
Number of subjects: 59
Study: 36436199

Group type: EXPERIMENTAL
Intervention: ICM implant with remote monitoring and symptom-triggered mobile app transmissions
Number of subjects: 477

Group type: COMPARATOR
Intervention: Non-ICM management and follow-up
Number of subjects: 477
Study: 33977624

Group type: EXPERIMENTAL
Intervention: Mutual aid relationships (family; family and intra-generational neighbors; family and multi-generational neighbors)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: No mutual aid
Number of subjects: 436
Study: 32169019

Group type: EXPERIMENTAL
Intervention: Oxytocin vaginal gel (400 IU, n=48)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (n=48)
Number of subjects: 96
Study: 35166715

Group type: EXPERIMENTAL
Intervention: Cortical Bone Trajectory (CBT) fixation
Number of subjects: 80
Study: 34548312

Group type: EXPERIMENTAL
Intervention: Procalcitonin guided antibiotics (n=195)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Usual care (n=122)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: UltraPro (n=152)
Number of subjects: 469
Study: 32331058

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (56 mg or 84 mg) in combination with newly initiated oral antidepressant (ESK+AD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral antidepressant + placebo nasal spray (AD+PBO)
Number of subjects: 0
Study: 35413861

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment thrice weekly for 4 weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: Topical diclofenac sodium gel (DSG) at a dose of 2 g over the affected joints per hand, applied four times per day for 4 weeks
Number of subjects: 108
Study: 33772892

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 169

Group type: COMPARATOR
Intervention: Cognitive processing therapy (CPT)
Number of subjects: 169
Study: 33833507

Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GLY) 25 µg twice-daily (BID)
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GLY) 25 µg BID
Number of subjects: 861

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 861
Study: 32410424

Group type: EXPERIMENTAL
Intervention: Multimodal analgesia (MA) therapy including oral administration of celecoxib before operation, local anesthetic wound infiltration during operation, and ice compression and oral administration of celecoxib after operation.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia pump (Control group).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multimodal analgesia (MA) therapy.
Number of subjects: 60
Study: 37045683

Group type: EXPERIMENTAL
Intervention: 1 + 1 schedule (doses at 3 and 12 months)
Number of subjects: 213

Group type: COMPARATOR
Intervention: 2 + 1 schedule (two primary doses and a booster)
Number of subjects: 213
Study: 33156372

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Active video gaming (AVG)
Number of subjects: 82
Study: 36366817

Group type: EXPERIMENTAL
Intervention: Two-limb mask
Number of subjects: 10

Group type: COMPARATOR
Intervention: One-limb mask
Number of subjects: 10
Study: 34420922

Group type: EXPERIMENTAL
Intervention: MibyeongBogam (MBBG) app
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 32420683

Group type: EXPERIMENTAL
Intervention: Lentils
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chickpeas
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: White Beans
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Postprandial metabolites
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 24 h urine samples
Number of subjects: 11
Study: 35168581

Group type: EXPERIMENTAL
Intervention: SMS technology
Number of subjects: 314

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: WBOTs
Number of subjects: 314
Study: 34134131

Group type: EXPERIMENTAL
Intervention: PCE risk score
Number of subjects: 7382

Group type: EXPERIMENTAL
Intervention: LS7 score
Number of subjects: 7382
Study: 32118713

Group type: EXPERIMENTAL
Intervention: HP and PHVHF group
Number of subjects: 30

Group type: COMPARATOR
Intervention: CVVH group
Number of subjects: 30
Study: 36316932

Group type: EXPERIMENTAL
Intervention: 100 mg nicotinamide 5 times a day for 2 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Routine treatment only
Number of subjects: 24
Study: 33977745

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification (CBM) for attention and interpretation training plus routine training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine training
Number of subjects: 100
Study: 35315603

Group type: EXPERIMENTAL
Intervention: DA‐2802 (tenofovir disoproxil orotate) at a dose of 319 mg once daily for 48 weeks
Number of subjects: 122

Group type: COMPARATOR
Intervention: Viread® (tenofovir disoproxil fumarate) at a dose of 300 mg once daily for 48 weeks
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: DA‐2802
Number of subjects: 122

Group type: COMPARATOR
Intervention: Viread®
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: DA‐2802 and Viread®
Number of subjects: 122
Study: 32462992

Group type: EXPERIMENTAL
Intervention: Recounting (n=16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Suppression (n=16)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 32
Study: 35085018

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture and lavender oil aromatherapy (verum group, n=39)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Combined sham auricular acupuncture and placebo oil aromatherapy (placebo group, n=41)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture and lavender oil aromatherapy (verum group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Combined sham auricular acupuncture and placebo oil aromatherapy (placebo group)
Number of subjects: 80
Study: 32017322

Group type: EXPERIMENTAL
Intervention: Exercise intervention (40 min, twice a week for 12 months)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 37